Enteric Viruses and Inflammatory Bowel Disease

Tarris, Georges; Rougemont, Alexis de; Charkaoui, Maeva; Michiels, Christophe; Martin, Laurent; Belliot, Gaël

doi:10.3390/v13010104

Cited by 40 publications

(41 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although NoV infections in AGE are mostly short and self-limited, chronic diarrhea in immunocompromised, malnourished, and elderly patients has been described [72][73][74]. On the other hand, immune-mediated disease may be triggered such as necrotizing enterocolitis in newborns [75,76] and inflammatory bowel disease exacerbations [77,78]. Dysregulation of enteric nervous and immune system may also be associated with the development of post-infectious irritable bowel syndrome [79,80].…”

Section: Clinical Presentationmentioning

confidence: 99%

Norovirus: Facts and Reflections from Past, Present, and Future

Lucero

Matson²,

Ashkenazi

et al. 2021

Viruses

View full text Add to dashboard Cite

Human Norovirus is currently the main viral cause of acute gastroenteritis (AGEs) in most countries worldwide. Nearly 50 years after the discovery of the “Norwalk virus” by Kapikian and colleagues, the scientific and medical community continue to generate new knowledge on the full biological and disease spectrum of Norovirus infection. Nevertheless, several areas remain incompletely understood due to the serious constraints to effectively replicate and propagate the virus. Here, we present a narrated historic perspective and summarize our current knowledge, including insights and reflections on current points of interest for a broad medical community, including clinical and molecular epidemiology, viral–host–microbiota interactions, antivirals, and vaccine prototypes. We also include a reflection on the present and future impacts of the COVID-19 pandemic on Norovirus infection and disease.

show abstract

Section: Clinical Presentationmentioning

confidence: 99%

Norovirus: Facts and Reflections from Past, Present, and Future

Lucero

Matson²,

Ashkenazi

et al. 2021

Viruses

View full text Add to dashboard Cite

show abstract

“…At least 37 G and 50 P genotypes of human and animal RVs have been distinguished (30). The most common combination of G and P genotypes of human RVs is G1P [8], G2P [4], G3P [8], G4P [8], and G9P [8], among which G1P [8] is the most prevalent worldwide (31). Caco-2 cells are similar to human intestinal epithelial cells in both structure and function, and are commonly used in in vitro experiments of RV infection (32).…”

Section: Discussionmentioning

confidence: 99%

“…The intestinal epithelium is shed and destroyed, and the migration of RV from the crypts to the cilia is accelerated, resulting in a temporary loss of intestinal absorption capacity, and severe watery diarrhea occurs when RV is colonized in the intestine (2). Although its infection rate dropped after vaccination began, RV is still common worldwide and is considered to be one of the major pathogens causing intestinal inflammation in infants and many young children (3,4). Every year, over 200 million children younger than 5 years old are infected with RV, resulting in more than 200,000 deaths worldwide (5).…”

Section: Introductionmentioning

confidence: 99%

Network pharmacology analysis and experimental study strategy reveals the potential mechanism of puerarin against rotavirus

Chen¹,

Lin²,

Cao³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background: This study aimed to explore the underlying mechanism of puerarin against rotavirus (RV), based on network pharmacology analysis and experimental study in vitro. Methods:The cytopathic effect inhibition assay with different concentrations of puerarin at different times of infection in vitro was applied to evaluate the effect of puerarin against human RV G1P[8] Wa strain (HRV Wa). Subsequently, the potential targets of puerarin and RV-related genes were obtained from online databases. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of the major target genes were also performed. Furthermore, the major targets and signaling pathway related to RV infection were verified at the molecular level via Western blot, quantitative real-time reverse transcription PCR (RT-qPCR), and Enzyme-linked immunosorbent assay (ELISA) tests.Results: Our results suggest that puerarin had a certain inhibitory effect on viral replication and proliferation. The network pharmacology analysis showed that a total of 436 puerarin corresponding target and 497 RV-related targets were acquired from the online databases. The core targets of puerarin against RV, such as Toll-like receptor 4 (TLR4), tumor necrosis factor (TNF), and caspase 3 (CASP3), were identified from the protein-protein interaction (PPI) network. The KEGG analysis indicated that the TLR signaling pathway was one of the crucial mechanisms of puerarin against RV. In particular, puerarin could inhibit the expression of key factors of the TLR4/nuclear factor kappa-B (NF-κB) signaling pathway in HRV-infected Caco-2 cells and regulate the levels of cellular inflammatory factors.Conclusions: Based on the network pharmacology analysis and experimental study, the study showed that puerarin not only had an anti-RV effect, but could also modulate the inflammatory response induced by RV infection via the TLR4/NF-κB signaling pathway. This study reveals the potential of puerarin in the treatment of RV infection, suggesting that it might be a promising therapeutic agent.

show abstract

“…Many studies showed that IBD patients have altered microbiome and pro-inflammatory bacteria. When you treat a patient with Crohn disease and make an ostomy avoid intestinal transit in affected bowel segment it result in decreased inflammation [10][11][12][13].…”

Section: Pathogenesismentioning

confidence: 99%

Current Elective Surgical Treatment of Inflammatory Bowel Disease

Oliveira¹,

Boiocchi²,

Bafutto³

et al. 2023

Current Topics in Colorectal Surgery

View full text Add to dashboard Cite

The incidence of inflammatory bowel disease (IBD) is increasing world-wide and most patient will require some surgical treatment once in life. IBD surgical patients are a challenge to surgeons. Main goals of surgical treatment are (1) to preserve the small bowel integrity because many resections may lead the patient to a small bowel short syndrome and (2) restore normal function as they have absorption disturbances. IBD patients may present mal-nutrition status and/or immunosuppression at the time of surgery. Types of surgery range from a simple plasty in Crohn disease to a total proctocolectomy in Ulcerative Colitis. For Crohn disease most procedures avoid resection and use diseased segments to prevent disabsorption. Herein we describe the most currently used techniques to treat IBD patients, when to indicate surgery and how to prepare them to less outcomes. Patients with Crohn disease with high risk for short bowel syndrome and intestinal failure should be submitted to Strictureplasty otherwise, Bowel Resection is the favored surgical technique for the management of fibrostenotic. Bowel Resection is associated with lower recurrence rate and longer recurrence-free survival.

show abstract

Enteric Viruses and Inflammatory Bowel Disease

Cited by 40 publications

References 96 publications

Norovirus: Facts and Reflections from Past, Present, and Future

Norovirus: Facts and Reflections from Past, Present, and Future

Network pharmacology analysis and experimental study strategy reveals the potential mechanism of puerarin against rotavirus

Current Elective Surgical Treatment of Inflammatory Bowel Disease

Contact Info

Product

Resources

About